Date: 2013-04-23
Type of information: Collaboration agreement
Compound: small molecules against multiple AstraZeneca targets
Company: AstraZeneca (UK) Alchemia (Australia)
Therapeutic area: Cancer - Oncology - Cardiovascular diseases - Metabolic diseases - Infectious diseass - Respiratory diseases - CNS diseases
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On April 23, 2013, Alchemia, an australian drug discovery and development company, has announced that it has signed a multi-target, drug discovery collaboration with AstraZeneca AB (AstraZeneca). This collaboration includes the use of the proprietary Diversity Scanning Array (DSA) and associated Versatile Assembly on Stable Templates (VAST) chemistry platform to discover and develop novel small molecules against multiple AstraZeneca targets. Alchemia will provide VAST chemistry expertise to develop small molecule clinical candidates for AstraZeneca. By accessing Alchemia’s VAST discovery platform, AstraZeneca will seek novel small molecules to treat diseases across a variety of therapeutic areas including oncology, respiratory, cardiovascular, metabolism, infection and neuroscience.
Alchemia has designed a suite of novel compounds that scans three dimensional molecular shapes and peptidomimetic functionality termed the Diversity Scanning Array (DSA). This array contains over 14,000 unique compounds related by their shape (chemoform) and/or by their functionality (motif, three binding elements). The DSA forms the basis for Alchemia’s VAST discovery platform which, when screened in high throughput screening (HTS), can identify the shape and binding elements required for target modulation. Hits from the DSA are related by shape and/or functionality and thus provide detailed structure activity relationships for rapid optimisation.
Financial terms: Under the terms of this Agreement, Alchemia will receive an undisclosed upfront payment and is
eligible for potential preclinical, clinical and commercial launch payments totalling up to $240M, as
well as a single digit royalty
Latest news:
